StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of NASDAQ GLMD opened at $4.73 on Tuesday. The firm has a market capitalization of $23.86 million, a price-to-earnings ratio of -1.97 and a beta of 0.67. The stock has a 50 day moving average price of $4.66 and a 200 day moving average price of $4.35. Galmed Pharmaceuticals has a 52-week low of $2.73 and a 52-week high of $23.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Further Reading
- Five stocks we like better than Galmed Pharmaceuticals
- What is the FTSE 100 index?
- When Is the Best Time to Invest in Mutual Funds?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Is NVIDIA Stock in a Correction or Consolidation?
- 10 Best Airline Stocks to Buy
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
